ZSTK3744 / Zenyaku Holdings - LARVOL DELTA

ZSTK3744, a novel aryl hydrocarbon receptor agonist, exhibits efficacy against chemotherapy-resistant triple-negative breast cancer. (PubMed, Cancer Res Commun) - "Compared with parental cells, these resistant cells exhibited reduced sensitivity to paclitaxel, adriamycin, and eribulin in the viability assays. These results suggest that ZSTK3744 combines robust cell growth-inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CYP1A1 • CYP1B1 • HER-2 • TIPARP

Aryl hydrocarbon receptor agonist ZSTK3744 overcomes chemotherapy resistance in TNBC (AACR 2025) - "Chemotherapy-resistant MDA-MB-468 cells, derived from TNBC, were developed through long-term exposure to adriamycin or paclitaxel. Moreover, ZSTK3744 significantly inhibited tumor growth in xenograft models implanted with adriamycin-resistant MDA-MB-468 cells, showing a higher potency than eribulin. ZSTK3744 is a promising agent for overcoming chemotherapy-resistance in TNBC."

Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ABCB1 • HER-2

ZSTK3744, a novel AhR agonist, demonstrates antitumor efficacy in TNBC cell lines in vitro and in vivo (AACR 2025) - "ZSTK3744 demonstrated potent antitumor effects on TNBC-derived cells in vitro and in vivo, as well as having a favorable safety profile. These results suggest that ZSTK3744 is suitable for development as a novel therapeutic agent for TNBC. Ongoing studies are needed to identify biomarkers that predict response to ZSTK3744."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer